Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Garon and colleagues demonstrate that the association of HLA supertype B44 with response to immune checkpoint blockade in melanoma but not NSCLC is related to differential mutational features that influence HLA binding of neoepitopes.
Bhardwaj et al. report that adding Flt3 ligand to the treatment strategy effectively increased DC populations and increased T-cell responses in a randomized phase II trial of a DC-targeted vaccine for the melanoma antigen NY-ESO-1.
Samstein et al. report that mutations in BRCA1 and BRCA2 result in distinct mutational genomic landscapes, effects on the tumor-immune microenvironment and response to immune checkpoint therapy.
Goel and colleagues show that CDK4/6 inhibition induces global chromatin changes mediated by AP-1 factors, which mediate key biological and clinical effects in breast cancer.
Quezada and colleagues develop improved anti-CD25 antibodies that preserve IL-2 signaling and enhance single-agent antitumor immunity and immunotherapy through specific and efficient Treg cell depletion.
Martin-Subero and colleagues analyze DNA methylation patterns in B-cell tumors and their normal cells of origin, and develop epiCMIT, a methylation-based mitotic clock with prognostic relevance.
David and colleagues uncover an inflammation-activated, progenitor-derived enhancer network hijacked by mutant Kras during pancreatic cancer initiation.
Jordan and colleagues show the role of increased fatty acid metabolism in AML stem cells, in both intrinsic and acquired resistance to combination venetoclax and azacitidine, and find that cells can be re-sensitized by inhibiting fatty acid oxidation.
Using lineage tracing and molecular profiling, Abate-Shen and colleagues identify a Ras and Myc co-activation signature that predicts metastasis and castration resistance in localized prostate cancer.
Han and colleagues develop a CAR T cell directed at GD2, a molecule overexpressed in retinoblastoma, which showed efficacy against murine retinoblastoma when combined with IL-15 in a hydrogel delivery system.
Limzerwala et al. show that FoxM1 insufficiency leads to chromosome segregation errors via RhoA modulation, causing tumor progression across different tissue types.
Gottlieb and colleagues show that stearoyl-CoA desaturase promotes metabolic adaptation of acute lymphoblastic leukemia cells to the central nervous system microenvironment, revealing a potential site-specific metabolic vulnerability of this disease.
Smith et al. report that age-associated mutations in mitochondrial DNA cause defects in oxidative phosphorylation. This results in metabolic rewiring, which subsequently contributes to accelerated development of colorectal cancer.
White and colleagues identify a role for host autophagy in restraining T-cell-dependent immune responses, specifically against tumors with high mutational burden.
Rossjohn, van der Vliet and colleagues develop single-domain antibodies binding composite CD1d and NKT T-cell receptor antigens, inducing specific antitumor immune subsets.
ARID1A/B loss causes oncogenic BAF complex redistribution. Zhu and colleagues show that concomitant ARID1A and ARID1B loss results in carcinogenesis and disruptive redistribution of residual cBAF subcomplexes, impairing pBAF function.
Erez and colleagues demonstrate that increased expression of arginosuccinate synthase under glucose deprivation leads to gluconeogenesis and increased purine synthesis, which when targeted can enhance response to immune checkpoint blockade.
Zhang and colleagues analyzed data from patient samples exposed to the BCL2 inhibitor venetoclax, approved for treatment of acute myeloid leukemia, identifying modes of therapy resistance and synthetic lethality with MCL1 inhibition.
Irvine and colleagues present a lipid nanoparticle platform containing self-replicating interleukin-12 RNA, which showed therapeutic efficacy in vivo by promoting immunogenic cell death and priming CD8+ T cells.